The nation of Zimbabwe has declined a major US healthcare agreement worth $367m (£272m) spanning five years because of Washington's request for sensitive information.
This move was revealed following a internal memorandum from December was leaked, revealing that President Emmerson Mnangagwa deemed the deal was "lopsided".
A government representative later clarified that the United States was requesting biological samples for research and profit while refused to share the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable process of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged further dialogue to secure a agreement suitable to all parties so the nation's vital HIV treatment initiative can proceed.
Wider Implications
This rejection follows a comparable case in neighbouring Kenya, where a high court blocked a related health funding agreement following legal challenges were raised about the security of Kenyans' health data.
Since returning to office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
The agency had administered assistance for the US government, but Trump argued its spending was "wasteful" and his government was seeking government-to-government deals to boost openness and accountability.
Based on reports, 16 nations in Africa have to date signed similar agreements, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment through US-supported programmes," the Ambassador said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"Effectively, our nation would supply the raw materials for medical research without any assurance that the final treatments would be available to our population if a new pandemic emerge."
National Interest and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral deals were undermining systems previously established via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to deal with potential global health emergencies.
"This system is intended to guarantee that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to develop them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how future collaboration might be designed in a manner that honours the sovereignty and interests of both nations."
Medical Community Reaction
Medical experts expressed it acknowledged the government's concerns, but recommended that negotiations need to persist since much of the country's Aids initiatives were funded by international support.
"If technical issues exist, such as those relating to information security or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it said.
The situation emphasises the ongoing challenges between receiving much-needed international aid and safeguarding national sovereignty in an ever more interconnected world.